Literature DB >> 26264743

Tricking the balance: NK cells in anti-cancer immunity.

Jens Pahl1, Adelheid Cerwenka2.   

Abstract

Natural Killer (NK) cells are classically considered innate immune effector cells involved in the first line of defense against infected and malignant cells. More recently, NK cells have emerged to acquire properties of adaptive immunity in response to certain viral infections such as expansion of specific NK cell subsets and long-lasting virus-specific responses to secondary challenges. NK cells distinguish healthy cells from abnormal cells by measuring the net input of activating and inhibitory signals perceived from target cells through NK cell surface receptors. Acquisition of activating ligands in combination with reduced expression of MHC class I molecules on virus-infected and cancer cells activates NK cell cytotoxicity and release of immunostimulatory cytokines like IFN-γ. In the cancer microenvironment however, NK cells become functionally impaired by inhibitory factors produced by immunosuppressive immune cells and cancer cells. Here we review recent progress on the role of NK cells in cancer immunity. We describe regulatory factors of the tumor microenvironment on NK cell function which determine cancer cell destruction or escape from immune recognition. Finally, recent strategies that focus on exploiting NK cell anti-cancer responses for immunotherapeutic approaches are outlined.
Copyright © 2015 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Cancer; Immunotherapy; Innate immunity; NK cell

Mesh:

Substances:

Year:  2015        PMID: 26264743     DOI: 10.1016/j.imbio.2015.07.012

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  76 in total

1.  Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.

Authors:  Lin Xiao; Dongzhi Cen; Haining Gan; Yan Sun; Nanqi Huang; Hanzhen Xiong; Qiongmei Jin; Liqun Su; Xuejuan Liu; Kejian Wang; Guangrong Yan; Tianfa Dong; Shangbiao Wu; Pengzhi Zhou; Jinshan Zhang; Weixiang Liang; Junlan Ren; Yaoshu Teng; Can Chen; Xue Hu Xu
Journal:  Mol Ther       Date:  2019-03-20       Impact factor: 11.454

2.  Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers.

Authors:  Ian MacFawn; Hannah Wilson; Luke A Selth; Ian Leighton; Ilya Serebriiskii; R Christopher Bleackley; Osama Elzamzamy; Joshua Farris; Phillip M Pifer; Jennifer Richer; Steven M Frisch
Journal:  Mol Immunol       Date:  2018-11-30       Impact factor: 4.407

3.  IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo.

Authors:  Margherita Boieri; Aina Ulvmoen; Amanda Sudworth; Clare Lendrem; Matthew Collin; Anne M Dickinson; Lise Kveberg; Marit Inngjerdingen
Journal:  Oncoimmunology       Date:  2017-01-17       Impact factor: 8.110

4.  TGF-βR inhibitor SB431542 restores immune suppression induced by regulatory B-T cell axis and decreases tumour burden in murine fibrosarcoma.

Authors:  Kavitha Premkumar; Bhavani S Shankar
Journal:  Cancer Immunol Immunother       Date:  2020-07-13       Impact factor: 6.968

5.  Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors.

Authors:  Sheila López-Cobo; Natalia Pieper; Carmen Campos-Silva; Eva M García-Cuesta; Hugh T Reyburn; Annette Paschen; Mar Valés-Gómez
Journal:  Oncoimmunology       Date:  2017-11-06       Impact factor: 8.110

6.  A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.

Authors:  Todd A Fehniger; Jeffrey S Miller; Robert K Stuart; Sarah Cooley; Amandeep Salhotra; Julie Curtsinger; Peter Westervelt; John F DiPersio; Timothy M Hillman; Nova Silver; Michael Szarek; Leonid Gorelik; Mark W Lowdell; Eric Rowinsky
Journal:  Biol Blood Marrow Transplant       Date:  2018-03-27       Impact factor: 5.742

7.  Soluble Fc-Disabled Herpes Virus Entry Mediator Augments Activation and Cytotoxicity of NK Cells by Promoting Cross-Talk between NK Cells and Monocytes.

Authors:  Qinglai Meng; Asifa K Zaidi; John Sedy; Armand Bensussan; Daniel L Popkin
Journal:  J Immunol       Date:  2019-02-15       Impact factor: 5.422

8.  Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.

Authors:  Armando M Marrufo; Stephen O Mathew; Pankaj Chaudhary; Joseph D Malaer; Jamboor K Vishwanatha; Porunelloor A Mathew
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

9.  Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression.

Authors:  R J Seager; Cynthia Hajal; Fabian Spill; Roger D Kamm; Muhammad H Zaman
Journal:  Converg Sci Phys Oncol       Date:  2017-07-28

10.  Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.

Authors:  Rizwan Romee; Maximillian Rosario; Melissa M Berrien-Elliott; Julia A Wagner; Brea A Jewell; Timothy Schappe; Jeffrey W Leong; Sara Abdel-Latif; Stephanie E Schneider; Sarah Willey; Carly C Neal; Liyang Yu; Stephen T Oh; Yi-Shan Lee; Arend Mulder; Frans Claas; Megan A Cooper; Todd A Fehniger
Journal:  Sci Transl Med       Date:  2016-09-21       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.